Every material Form 8-K Sabra Health Care REIT filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Clifton J. Porter II told Sabra's board on November 7, 2024, that he will not stand for reelection at the 2025 annual shareholder meeting. The filing says the decision does not involve any disagreement over the company's operations, policies or practices.
Notice given to the board on November 7, 2024
Porter will not stand for reelection at the 2025 annual meeting of shareholders
Filing states no disagreement with the company's operations, policies or practices
Porter is set to become President and CEO of AHCA/NCAL
Sabra Health Care REIT reported third-quarter 2024 net income of $29.8 million, or $0.13 per diluted share, compared with a net loss of $15.1 million, or $0.07 per share, a year earlier. Total revenues rose to $178.0 million from $161.6 million. The company raised the low and high ends of its 2024 normalized FFO guidance and raised the midpoint of its normalized AFFO guidance, but lowered the top end of its net income guidance.
Q3 2024 normalized FFO was $0.35 per diluted share, versus $0.33 in Q3 2023; normalized AFFO was $0.37, versus $0.34.
2024 normalized FFO guidance raised to $1.39-$1.40 from $1.36-$1.39; normalized AFFO guidance raised to $1.43-$1.44 from $1.41-$1.44.
2024 net income guidance is $0.48-$0.49, down from the prior top end of $0.51.
Board declared a quarterly dividend of $0.30 per share, payable November 29, 2024, to holders of record on November 15, 2024.
Sabra Health Care REIT reported second-quarter 2024 net income of $0.10 per diluted share, up from $0.09 a year earlier, and raised its 2024 earnings guidance ranges. The company also declared a quarterly dividend of $0.30 per share, which matters to shareholders because it reflects both higher reported earnings and the updated outlook.
Q2 2024 net income was $0.10 per diluted share versus $0.09 in Q2 2023; FFO was $0.35 versus $0.32
2024 guidance raised: net income $0.48-$0.51, Normalized FFO $1.36-$1.39, Normalized AFFO $1.41-$1.44 per diluted share
Quarterly dividend of $0.30 per share declared August 7, 2024, payable August 30, 2024 to holders of record on August 19, 2024
Net Debt to Adjusted EBITDA was 5.45x as of June 30, 2024; liquidity was approximately $906.0 million
Sabra Health Care REIT reported first quarter 2024 net income of $26.3 million, or $0.11 per diluted share, compared with a net loss of $9.5 million, or $0.04 per share, a year earlier. Total revenues rose to $166.7 million from $161.3 million, and the company reiterated its 2024 earnings guidance.
Q1 2024 normalized FFO was $0.34 per diluted share, up from $0.33 a year earlier; normalized AFFO was $0.35, up from $0.34.
Total revenues were $166.7 million, up from $161.3 million; senior housing managed portfolio operating expenses rose to $49.7 million from $43.6 million.
2024 guidance reiterated: normalized FFO of $1.34 to $1.38 per diluted share and normalized AFFO of $1.39 to $1.43, assuming no 2024 acquisitions or dispositions.
Board declared a quarterly dividend of $0.30 per share, payable May 31, 2024, to holders of record as of May 20, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sabra Health Care REIT filing is on SEC EDGAR ↗. 8-K briefs of other companies →